Revenio Group Corporation: iCare and Evolucare have launched a distribution partnership in AI solutions

iCare and Evolucare have launched a distribution partnership in AI solutions

iCare and OphtAI, a French Evolucare Technologies company, have launched a distribution partnership. iCare will now offer OphtAI analysis in EMEA and Canada for its iCare ILLUME retinal screening solution based on retinal images.

OphtAI is one of the most advanced AI retinal image analysis providers. The iCare ILLUME retinal screening solution uses AI-generated image analysis for diabetic retinopathy screening and, in the future, for other eye diseases. The iCare ILLUME solution supports clinical decision-making and is based on high-quality image data produced by iCare's retinal imaging devices and cloud-based software solutions. AI enables the efficient processing of large numbers of images, thereby improving screening accessibility. This holistic solution optimizes patient care pathways and the processes of eye care professionals.
 
"Our mission is to keep the wonderful world visible to everyone. We are one of the leading developers of eye diagnostic devices, and our software solutions are increasingly important in eye care pathways. Through this partnership, we further strengthen our offering by providing our customers with more options, each with its benefits. All our solutions have top-notch performance, and we have validated the OphtAI solution's performance in diabetic retinopathy screening. OphtAI is particularly strong in the French market, where EDC Lamy will continue as our valued exclusive distributor for imaging devices. We see opportunities for expansion into new geographical areas through our collaboration," says Pirjo Kortteisto, Business Line Director at Icare Finland.

"Based on our previous partnerships, we have seen that the OphtAI solution is perfectly in line with the needs of optical professionals, making AI increasingly essential in healthcare. The integration of OphtAI into iCare ILLUME proves that AI can be intelligently integrated into practitioners' tools. We are convinced that it will add value to the daily work of optometrists and ophthalmologists," says Alexandre Le Guilcher, Innovation Director at Evolucare Technologies.

 
Further information
Pirjo Kortteisto, Business Line Director
[email protected]  
 
Distribution
Major media
www.reveniogroup.fi
 
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
 
In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
 
iCare in brief
iCare is a Finnish company that develops and manufactures innovative retinal imaging devices and software solutions for the diagnosis and screening of eye diseases. iCare's vision is to keep the world visible to everyone, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare is part of Nasdaq Helsinki-listed Revenio Group Corporation.

Evolucare Technologies and the OphtAI Solution in brief
OphtAI was born in France from Evolucare, a company dedicated to IT healthcare with over 35 years of experience. OphtAI is a CE-marked Class IIA medical device set to revolutionize eye disease screening and diagnosis with its state-of-the-art Artificial Intelligence.

OphtAI's solution results from years of collaborative research with the 41 Public AP-HP Hospitals with a database of 800,000 retinal images. OphtAI intends to improve care for billions of people at risk of blindness worldwide by covering all the specialty's needs, from private practices to hospital clinics and mobile operations, and adapting to all workflows. OphtAI can detect signs of retinal pathologies in a few seconds by analyzing retina photos: Diabetic Retinopathy and Macular Edema, Glaucoma, and AMD. Its subsequent implementations will extend these with a portfolio of both rare and frequent diseases. It is available as a flexible teleophthalmology platform, integrated with most fundus cameras, and easily interfaced with ophthalmology specialty software.